MTOR and melanoma: Consistently, topotecan treatment decreased SIRT1 expression, phosphorylation of Akt at Ser473 and mTOR at Ser2448, as well as EMT activity, but had minimal effects in USP22‐deficient melanoma cells (Figure S6D).